Thomas J. Schall, President and CEO at ChemoCentryx, Inc. (CCXI), sold 272,104 shares at $41.46 ($11.3M) on 2020-01-17, disclosed to the SEC on 2020-01-17.
Seasonal sale ($11.3M) by President and CEO — this insider has traded CCXI in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.01 | 30,317 | $1.2M | 11.0% |
| 2 | $41.01 | 30,317 | $1.2M | 11.0% |
| 3 | $41.46 | 83,556 | $3.5M | 30.7% |
| 4 | $41.46 | 83,556 | $3.5M | 30.7% |
| 5 | $42.13 | 22,179 | $934K | 8.3% |
| 6 | $42.13 | 22,179 |
| $934K |
| 8.3% |
| Total | $41.47 avg | 272,104 | $11.3M | 100% |
| Filing → |
| IMRX | BUY | 2025-06-18 | $179K | — | Filing → |
| IMRX | BUY | 2024-03-25 | $7K | — | Filing → |
| CCXI | SELL | 2022-08-08 | $6.5M | — | Filing → |